TCR Vβ usage by acetylcholine receptor-specific CD4+ T cells in myasthenia gravis

Raghavan Pillai Raju, Duraiswamy Navaneetham, Maria Pia Protti, Robert M. Norton, Bobbi L. Hoppe, James Howard, Bianca M. Conti-Fine

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In myasthenia gravis the muscle acetylcholine receptor (AChR) is the target of an autoimmune response. AChR epitopes recognized by CD4+ T cells in myasthenic patients have been identified. AChR-specific CD4+ cell lines can be propagated by stimulation of blood lymphocytes with synthetic or biosynthetic AChR sequences. We analysed, using a semi-quantitative PCR assay, the T cell receptor (TCR) Vβ usage of 16 anti-AChR polyclonal CD4+ T cell lines of known epitope specificity, propagated from myasthenic patients using pools of overlapping peptides corresponding to the sequence of an AChR subunit, or individual synthetic AChR sequences. Twelve lines had been propagated for less than 2 months, four lines for 3.5-5 months. Most lines had limited Vβ usage, but in most cases different Vβ regions were used for different epitopes in the same patient, and for the same epitope in different patients. In a few patients, the same Vβ regions were used for recognition of different epitopes. The Vβ4 and Vβ6 regions were used most frequently. These findings suggest that the potentially autoimmune T cells that survive clonal deletion have a limited TCR repertoire. Although the present data do allow conclusions on the role of a superantigen in triggering the anti-AChR autoimmune response, the finding that different Vβ regions were used in different patients does not support an important role of a superantigen in the maintenance of the CD4+ response in myasthenia gravis.

Original languageEnglish (US)
Pages (from-to)203-217
Number of pages15
JournalJournal of Autoimmunity
Volume10
Issue number2
DOIs
StatePublished - Jan 1 1997
Externally publishedYes

Fingerprint

Myasthenia Gravis
Cholinergic Receptors
T-Cell Antigen Receptor
T-Lymphocytes
Epitopes
Superantigens
Muscle Weakness
Autoimmunity
Artificial Receptors
Clonal Deletion
Cell Line
Lymphocyte Activation
Maintenance
Muscles
Polymerase Chain Reaction
Peptides

Keywords

  • autoimmunity
  • myasthenia gravis
  • PCR
  • preferential TCR Vβ usage
  • T cell epitopes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Raju, R. P., Navaneetham, D., Protti, M. P., Norton, R. M., Hoppe, B. L., Howard, J., & Conti-Fine, B. M. (1997). TCR Vβ usage by acetylcholine receptor-specific CD4+ T cells in myasthenia gravis. Journal of Autoimmunity, 10(2), 203-217. https://doi.org/10.1006/jaut.1996.0120

TCR Vβ usage by acetylcholine receptor-specific CD4+ T cells in myasthenia gravis. / Raju, Raghavan Pillai; Navaneetham, Duraiswamy; Protti, Maria Pia; Norton, Robert M.; Hoppe, Bobbi L.; Howard, James; Conti-Fine, Bianca M.

In: Journal of Autoimmunity, Vol. 10, No. 2, 01.01.1997, p. 203-217.

Research output: Contribution to journalArticle

Raju, RP, Navaneetham, D, Protti, MP, Norton, RM, Hoppe, BL, Howard, J & Conti-Fine, BM 1997, 'TCR Vβ usage by acetylcholine receptor-specific CD4+ T cells in myasthenia gravis', Journal of Autoimmunity, vol. 10, no. 2, pp. 203-217. https://doi.org/10.1006/jaut.1996.0120
Raju, Raghavan Pillai ; Navaneetham, Duraiswamy ; Protti, Maria Pia ; Norton, Robert M. ; Hoppe, Bobbi L. ; Howard, James ; Conti-Fine, Bianca M. / TCR Vβ usage by acetylcholine receptor-specific CD4+ T cells in myasthenia gravis. In: Journal of Autoimmunity. 1997 ; Vol. 10, No. 2. pp. 203-217.
@article{baa05467577e4f089b6534090bbd723c,
title = "TCR Vβ usage by acetylcholine receptor-specific CD4+ T cells in myasthenia gravis",
abstract = "In myasthenia gravis the muscle acetylcholine receptor (AChR) is the target of an autoimmune response. AChR epitopes recognized by CD4+ T cells in myasthenic patients have been identified. AChR-specific CD4+ cell lines can be propagated by stimulation of blood lymphocytes with synthetic or biosynthetic AChR sequences. We analysed, using a semi-quantitative PCR assay, the T cell receptor (TCR) Vβ usage of 16 anti-AChR polyclonal CD4+ T cell lines of known epitope specificity, propagated from myasthenic patients using pools of overlapping peptides corresponding to the sequence of an AChR subunit, or individual synthetic AChR sequences. Twelve lines had been propagated for less than 2 months, four lines for 3.5-5 months. Most lines had limited Vβ usage, but in most cases different Vβ regions were used for different epitopes in the same patient, and for the same epitope in different patients. In a few patients, the same Vβ regions were used for recognition of different epitopes. The Vβ4 and Vβ6 regions were used most frequently. These findings suggest that the potentially autoimmune T cells that survive clonal deletion have a limited TCR repertoire. Although the present data do allow conclusions on the role of a superantigen in triggering the anti-AChR autoimmune response, the finding that different Vβ regions were used in different patients does not support an important role of a superantigen in the maintenance of the CD4+ response in myasthenia gravis.",
keywords = "autoimmunity, myasthenia gravis, PCR, preferential TCR Vβ usage, T cell epitopes",
author = "Raju, {Raghavan Pillai} and Duraiswamy Navaneetham and Protti, {Maria Pia} and Norton, {Robert M.} and Hoppe, {Bobbi L.} and James Howard and Conti-Fine, {Bianca M.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1006/jaut.1996.0120",
language = "English (US)",
volume = "10",
pages = "203--217",
journal = "Journal of Autoimmunity",
issn = "0896-8411",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - TCR Vβ usage by acetylcholine receptor-specific CD4+ T cells in myasthenia gravis

AU - Raju, Raghavan Pillai

AU - Navaneetham, Duraiswamy

AU - Protti, Maria Pia

AU - Norton, Robert M.

AU - Hoppe, Bobbi L.

AU - Howard, James

AU - Conti-Fine, Bianca M.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - In myasthenia gravis the muscle acetylcholine receptor (AChR) is the target of an autoimmune response. AChR epitopes recognized by CD4+ T cells in myasthenic patients have been identified. AChR-specific CD4+ cell lines can be propagated by stimulation of blood lymphocytes with synthetic or biosynthetic AChR sequences. We analysed, using a semi-quantitative PCR assay, the T cell receptor (TCR) Vβ usage of 16 anti-AChR polyclonal CD4+ T cell lines of known epitope specificity, propagated from myasthenic patients using pools of overlapping peptides corresponding to the sequence of an AChR subunit, or individual synthetic AChR sequences. Twelve lines had been propagated for less than 2 months, four lines for 3.5-5 months. Most lines had limited Vβ usage, but in most cases different Vβ regions were used for different epitopes in the same patient, and for the same epitope in different patients. In a few patients, the same Vβ regions were used for recognition of different epitopes. The Vβ4 and Vβ6 regions were used most frequently. These findings suggest that the potentially autoimmune T cells that survive clonal deletion have a limited TCR repertoire. Although the present data do allow conclusions on the role of a superantigen in triggering the anti-AChR autoimmune response, the finding that different Vβ regions were used in different patients does not support an important role of a superantigen in the maintenance of the CD4+ response in myasthenia gravis.

AB - In myasthenia gravis the muscle acetylcholine receptor (AChR) is the target of an autoimmune response. AChR epitopes recognized by CD4+ T cells in myasthenic patients have been identified. AChR-specific CD4+ cell lines can be propagated by stimulation of blood lymphocytes with synthetic or biosynthetic AChR sequences. We analysed, using a semi-quantitative PCR assay, the T cell receptor (TCR) Vβ usage of 16 anti-AChR polyclonal CD4+ T cell lines of known epitope specificity, propagated from myasthenic patients using pools of overlapping peptides corresponding to the sequence of an AChR subunit, or individual synthetic AChR sequences. Twelve lines had been propagated for less than 2 months, four lines for 3.5-5 months. Most lines had limited Vβ usage, but in most cases different Vβ regions were used for different epitopes in the same patient, and for the same epitope in different patients. In a few patients, the same Vβ regions were used for recognition of different epitopes. The Vβ4 and Vβ6 regions were used most frequently. These findings suggest that the potentially autoimmune T cells that survive clonal deletion have a limited TCR repertoire. Although the present data do allow conclusions on the role of a superantigen in triggering the anti-AChR autoimmune response, the finding that different Vβ regions were used in different patients does not support an important role of a superantigen in the maintenance of the CD4+ response in myasthenia gravis.

KW - autoimmunity

KW - myasthenia gravis

KW - PCR

KW - preferential TCR Vβ usage

KW - T cell epitopes

UR - http://www.scopus.com/inward/record.url?scp=0031128368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031128368&partnerID=8YFLogxK

U2 - 10.1006/jaut.1996.0120

DO - 10.1006/jaut.1996.0120

M3 - Article

C2 - 9185882

AN - SCOPUS:0031128368

VL - 10

SP - 203

EP - 217

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

SN - 0896-8411

IS - 2

ER -